Ottawa, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market size is predicted to increase from USD 3.01 billion in 2025 to approximately USD 5.68 billion by 2033, ...
The glioblastoma multiforme (GBM) treatment market size is on a steep growth trajectory, rising from $2.73 billion in 2025 to $ ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...
Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...
Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM) ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results